A
Ancora Innovation
Innovative small molecule regulators targeting GIRK channels, circadian rhythms, and bacterial systems for advanced drug discovery
About Ancora Innovation
Ancora Innovation operates in the biotechnology sector, focusing on the development of small molecule regulators that target G protein Inward Rectifying Potassium (GIRK) ion channels, circadian rhythms, and bacterial two-component systems. The company collaborates with various research institutions, including UCSF, SRI International, and the National Center for Advancing Translational Sciences, part of the NIH, to advance its drug discovery projects. Ancora Innovation serves pharmaceutical companies and research institutions, providing them with novel therapeutic solutions and research tools. The business model revolves around licensing and co-development partnerships, allowing the company to monetize its innovations through commercial markets. Ancora Innovation generates revenue by licensing its technology and entering into co-development agreements with larger pharmaceutical firms. The company is led by a team of experienced scientists with strong backgrounds in life sciences, molecular biology, and drug discovery.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- New York City, United States
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Deerfield
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ancora Innovation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ancora Innovation on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.